GHK-Cu has some human evidence in topical skin and wound-related settings, but the results are limited and mixed. That evidence does not establish injectable GHK-Cu as an effective or well-characterised treatment.
Still uncertain: Systemic benefits, long-term injectable safety and equivalence of research vials are not established.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Copper-binding tripeptide complex
Entity type
Peptide
Research focus
Skin, wound healing, collagen, hair/cosmetic research
Human evidence
Human evidence is route-specific and mixed. A randomized venous-ulcer study of topical 0.4% copper-tripeptide cream found no superiority over vehicle, and a 13-person randomized post-CO2-laser study found no significant objective skin benefit, although subjective satisfaction favored treatment. Injectable/systemic evidence remains much weaker.
Regulatory status
Injectable GHK-Cu is not an FDA-approved therapeutic product; FDA highlights compounded-injection safety uncertainty.
Main limitations
Systemic benefits, long-term injectable safety and equivalence of research vials are not established.
Safety
Route matters. FDA notes limited human safety data for injectable GHK-Cu and potential immunogenicity/impurity concerns.
Evidence reviewed
2026-09-18
i
Human evidence is route-specific and mixed. A randomized venous-ulcer study of topical 0.4% copper-tripeptide cream found no superiority over vehicle, and a 13-person randomized post-CO2-laser study found no significant objective skin benefit, although subjective satisfaction favored treatment. Injectable/systemic evi…
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Route matters. FDA notes limited human safety data for injectable GHK-Cu and potential immunogenicity/impurity concerns.
Topical products can cause local irritation; injectable/systemic GHK-Cu lacks a robust human safety dataset. Route, sterility, purity and copper exposure matter.
Technical details
Mechanism / biologyCopper-bound GHK influences extracellular-matrix, wound-remodelling and gene-expression pathways.
Route / formulation boundaryTopical cosmetic evidence cannot be automatically extrapolated to injected GHK-Cu.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceVerified topical human study exposure added; injectable dosing not established. A 0.4% topical tripeptide-copper cream was studied in a randomized human wound-ulcer trial and did not outperform vehicle placebo. This is route-specific research evidence and must not be converted into an injectable dose.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
2outcome records
7linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
